::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

SERUM LACTATE DEHYDROGENASE 2 ISOENZYME AS BONE MARROW INFILTRATION MARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA

AUTHORS:

Dr Aamna Arif , Dr Bushra Khaliq, Dr Sheikh Ali Ahmad Ajmal

ABSTRACT:

Objectives: To assess the level of serum lactate dehydrogenase 2 (LD2) in patients with NHL with and without bone marrow infiltration. Place and Duration: In the Oncology department of Mayo Hospital, Lahore for one-year duration from September 2019 to September 2020. Introduction: Lactate dehydrogenase (LDH) is often elevated in patients with hematopoietic tumors and has been shown to be prognostic, especially in patients with non-Hodgkin's lymphoma (NHL). The level of the LD2 isoenzyme in the serum was determined in 60 already diagnosed patients with NHL. Aims and Objectives: The patients were divided into two groups, 30 patients with bone marrow infiltration (group B) and the rest without infiltration (group C). The values were compared with 20 healthy controls matched for age and sex (Group A). Estimates were made before starting chemotherapy. Results: LD2 level was significantly increased in NHL patients compared to the control group. There was also a significant difference when the values were compared between NHL patients with and without bone marrow infiltration. The levels showed a positive correlation with the extent of the disease. Conclusion: We conclude that the above-mentioned non-invasive parameter is a useful indicator of the severity of the disease. Keywords: non-Hodgkin's lymphoma, mucosa-associated lymphoid tissue, Hodgkin's disease, lactate dehydrogenase.